15
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Artificial Intelligence in Gastroenterology

      Submit here before May 31, 2024

      About Digestion: 3.2 Impact Factor I 6.4 CiteScore I 0.914 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User’s Guide: An Update

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years. Summary: This review article aimed to provide an update on recent advances in TNF antagonist therapy for IBDs. Key Messages: Their position in the treatment algorithm has evolved to “rapid step-up therapy” or “top-down therapy” according to disease severity and patients’ characteristics. Limitations of anti-TNF antagonists include loss of response in up to 30–50% of patients with or without the development of antibodies. Therapeutic drug monitoring should provide a tailored, personalized approach to this scenario. Recently, biosimilar agents have been approved for IBDs and are considered equivalent in efficacy to the originator.

          Related collections

          Most cited references69

          • Record: found
          • Abstract: found
          • Article: not found

          3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.

          This paper is the first in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn's disease. Surgical management as well as special situations including management of perianal Crohn's disease of this ECCO Consensus are covered in a subsequent second paper [Gionchetti et al JCC 2016].
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

                Bookmark

                Author and article information

                Journal
                DIG
                Digestion
                10.1159/issn.0012-2823
                Digestion
                S. Karger AG
                978-3-318-06693-7
                978-3-318-06694-4
                0012-2823
                1421-9867
                2020
                September 2020
                31 July 2020
                : 101
                : Suppl 1
                : 16-26
                Affiliations
                [_a] aCrohn’s and Colitis Center, Gastroenterologie Beaulieu and Division of Gastroenterology and Hepatology, CHUV, Lausanne, Switzerland
                [_b] bDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kantonsspital Sankt Gallen, St. Gallen, Switzerland
                [_c] cDepartment of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, Switzerland
                [_d] dCentre sédunois de Gastroentérologie, Sion, Switzerland
                [_e] eInflammatory Bowel Disease Unit and Gastro-Immunology Laboratory Sheba Medical Center Tel-Aviv University, Tel-Aviv, Israel
                Author notes
                *Dr. Marianne Vullièmoz, Gastroentérologie Beaulieu SA, Avenue Jomini 8, CH–1004 Lausanne (Switzerland), mvulliemoz@gesb.ch
                Author information
                https://orcid.org/0000-0002-0947-5235
                Article
                506898 Digestion 2020;101(suppl 1):16–26
                10.1159/000506898
                32739923
                a804d472-6ecc-43f4-885b-0ed46ff1e8a8
                © 2020 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 06 August 2019
                : 01 March 2020
                Page count
                Figures: 1, Tables: 3, Pages: 11
                Categories
                Review

                Oncology & Radiotherapy,Gastroenterology & Hepatology,Surgery,Nutrition & Dietetics,Internal medicine
                Infliximab,Ulcerative colitis,TNF inhibitors,Crohn’s disease,Inflammatory bowel diseases,Biologicals

                Comments

                Comment on this article